Interaction between 5-fluorouracil, [6RS]leucovorin, and recombinant human interferon-alpha 2a in cultured colon adenocarcinoma cells

Cancer Commun. 1991 Jul;3(7):225-31. doi: 10.3727/095535491820873236.

Abstract

Recombinant human interferon-alpha 2a (rIFN-alpha 2a; 500 or 5,000 IU/mL) or [6RS] leucovorin ([6RS]LV; 1 microM) each potentiated the cytotoxic activity of 5-fluorouracil (FUra) by 2.6- to 3.2-fold during 72 hr exposures in two human colon adenocarcinoma cell lines (GC3/c1; VRC5/c1). When all three agents were combined, FUra cytotoxicity was further potentiated by 3.2- to 4.3-fold (total 10- to 14-fold). Potentiation of FUra cytotoxicity occurred at clinically achieveable concentrations of rIFN-alpha 2a and [6RS]LV. Effects were reversed by dThd (20 microM), although the activity of CB3717, a quinazoline-based, specific inhibitor of thymidylate synthase, was not potentiated by rIFN-alpha 2a. Data suggest the requirement of a 5-fluoropyrimidine for biochemical modulation and interaction at the level of thymidylate synthase or DNA.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adenocarcinoma
  • Cell Survival / drug effects
  • Colonic Neoplasms
  • Drug Synergism
  • Fluorouracil / administration & dosage*
  • Folic Acid / analogs & derivatives
  • Folic Acid / pharmacology
  • Interferon Type I / administration & dosage
  • Interferon Type I / pharmacology*
  • Leucovorin / administration & dosage
  • Leucovorin / pharmacology*
  • Quinazolines / pharmacology
  • Recombinant Proteins
  • Thymidylate Synthase / antagonists & inhibitors
  • Tumor Cells, Cultured / drug effects*

Substances

  • Interferon Type I
  • Quinazolines
  • Recombinant Proteins
  • CB 3717
  • Folic Acid
  • Thymidylate Synthase
  • Leucovorin
  • Fluorouracil